Dotolo_Caroline

Caroline Dotolo

Dotolo_Caroline

Caroline Dotolo

Partner

  • Vice Chair, Corporate Practice
Boston + 1 617 526 6723

Caroline Dotolo is Vice Chair of the Corporate Practice and provides in-depth counsel to public and private companies on day-to-day corporate matters and complex business transactions, including capital markets transactions, SEC disclosure and exchange listing compliance, corporate governance, mergers and acquisitions, joint ventures, and general corporate law. Her practice reflects significant experience advising issuers, investors and underwriters across industries such as life sciences, technology, and financial services, among many others, guiding clients from early-stage financing through complex public offerings.

Ms. Dotolo also regularly advises early-stage companies on matters such as formation and founder issues, equity structure, financing and governance, and also provides pro bono representation for nonprofit organizations. Her transactional perspective is informed by prior experience with civil and criminal matters, including work in the Economic Crimes Unit of the Civil Division at the US Attorney's Office in Boston.

The American Lawyer named Ms. Dotolo a 2023 Newest Leader in the Law in the publication’s New England Legal Awards, recognizing extraordinary attorneys with impressive accomplishments early in their careers. In 2022, she was named to Massachusetts Lawyers Weekly’s list of Up & Coming Lawyers for distinguishing herself as a rising star in the local legal community within her first ten years of practice.

 

Experience

  • Ms. Dotolo has represented either the issuer or the underwriters in numerous IPOs, follow-on offerings and other equity and debt offerings, including the following:

    • Akebia Therapeutics in its $50 million follow-on public offering
    • Inozyme Pharma in its $128.8 million initial public offering, $73.1 million follow-on offering and $69 million follow-on offering
    • Curis in its $15.1 million registered direct offering
    • Disc Medicine in its $157.8 million follow-on public offering
    • Solid Biosciences in its numerous private placements and $200 million follow-on public offering
    • Cue Biopharma in its $30 million private placement 
    • Syros Pharmaceuticals in its $130 million and $11.3 million private placements
    • Fulcrum Therapeutics in its $72 million initial public offering, $68.5 million private placement, $50.6 million follow-on offering and $144.2 million follow-on offering
    • Arvinas in its $459.9 million follow-on offering and $350 million private placement
    • Editas in its $215.6 million follow-on offering
    • A clinical-stage pharmaceutical company in its $52 million private placement
    • Altiostar Networks in numerous venture financings
    • Trevi Therapeutics in its $55 million initial public offering
    • Constellation Pharmaceuticals in its $60 million initial public offering
    • Flywire in numerous venture financings
    • Idera Pharmaceuticals in its $52.5 million, $57.5 million, $40 million, $27.7 million and $16.5 million follow-on offerings
    • Spark Therapeutics in its $402.5 million follow-on offering
    • An American investment management firm in its public offering of $300 million in senior notes
    • Merrimack Pharmaceuticals in its 144A offering of $175 million in senior notes
    • Bellerophon Therapeutics in its $60 million initial public offering  
  • Ms. Dotolo regularly advises public companies in the establishment of "at-the-market" sales arrangements, PIPEs and strategic equity transactions.
  • Ms. Dotolo also represents private companies in various stages of development, including in venture capital and strategic financings.

Recognition

Insights & News

View all of Caroline's insights & news

Credentials

  • Education

    • JD, Boston University School of Law, 2012

      Boston University Law Review, Co-Director, Student Advisor Program, Women’s Law Association

    • BA, History and Sociology, The Ohio State University, 2008

      magna cum laude Honors Program

    • Harvard Business School Online

      Credential of Readiness (CORe), Business Analytics, Financial Accounting, Economics for Managers, with High Honors, 2015

  • Admissions

    • Massachusetts

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel